MedTrace Logo

A Study of IMRT in Primary Bone and Soft Tissue Sarcoma

NCT02520128 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 191

Last updated 2020-12-02

No results posted yet for this study

Summary

IMRiS is a phase II trial which aims to assess the feasibility, efficacy and toxicity of Intensity Modulated Radiotherapy (IMRT) in three different cohorts of patients with primary bone and soft tissue sarcoma and to demonstrate whether IMRT can improve on current clinical outcomes.

Cohort 1 of the trial is now closed to recruitment.

Conditions

  • Soft Tissue Sarcoma, Adult
  • Ewing Sarcoma
  • Bone Sarcoma
  • Chordoma

Interventions

RADIATION

Intensity modulated radiotherapy (IMRT)

Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • NCRI Radiotherapy Trials QA (RTTQA) Group

    collaborator UNKNOWN

  • University College, London

    lead OTHER

Principal Investigators

  • Beatrice Seddon, Ph.D., M.D · University College London Hospitals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02520128 on ClinicalTrials.gov